Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study Meeting Abstract
| Authors: | von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; Marlton, P.; Dreyling, M.; Yoon, D. H.; Hess, G.; Radford, J.; Wiebking, V.; Yin, S.; Cybulski, E.; Turner, D. C.; Huang, H.; Zhou, M.; Penuel, E.; Wei, M. C.; Sehn, L. H. |
| Abstract Title: | Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 206 |
| End Page: | 207 |
| Language: | English |
| ACCESSION: | WOS:001091456900449 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: P400 -- Source: Wos |
